

**Title 20—DEPARTMENT OF
COMMERCE AND INSURANCE
Division 2220—State Board of Pharmacy
Chapter 2- General Rules**

PROPOSED RULE

20 CSR 2220-2.195 Prospective Drug Utilization Review

PURPOSE: This rule establishes requirements for prospective drug utilization review prior to dispensing a prescription or medication order.

(1) Prospective Drug Review.

- (A)** Prior to dispensing or otherwise approving medication for patient use, pharmacists shall use their professional judgment to review available patient records to assess therapeutic appropriateness.
- (B)** The pharmacist shall take appropriate steps within their professional judgment to address or resolve identified therapeutic appropriateness issues. Prospective drug review may only be performed by a pharmacist or an intern pharmacist working under the supervision of a Missouri licensed pharmacist.

AUTHORITY: sections 338.100 and 338.280, RSMo 2016, and sections 338.035 and 338.140, RSMo Cum Supp. 2020. Original rule filed: September 1, 2020.

PUBLIC COST: This proposed rule will not cost state agencies more than five hundred dollars (\$500) in the aggregate.

PRIVATE COST: This proposed rule will cost private entities approximately three hundred thirty thousand three hundred sixty-one dollars and fifty cents (\$330,361.50) annually for the life of the rule. It is anticipated that the costs will recur for the life of the rule, may vary with inflation, and are expected to increase at the rate projected by the Legislative Oversight Committee.

*NOTICE TO SUBMIT COMMENTS: Anyone may file a statement in support of or in opposition to this proposed rule with the Missouri Board of Pharmacy, PO Box 625, 3605 Missouri Boulevard, Jefferson City, MO 65102, by facsimile at (573) 526-3464, or via email at pharmacy@pr.mo.gov. To be considered, comments must be received within thirty (30) days after publication of this rule in the **Missouri Register**. No public hearing is scheduled.*